Floatz logo

Imgn632

Recurrent T Acute Lymphoblastic Leukemia

Children's Oncology GroupPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Recurrent T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Imgn632 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
mixed phenotype acute leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →